Zanubrutinib (Brukinsa, BeiGene) is a covalent, second-generation BTK inhibitor. 

When is Zanubrutinib Used for CLL?

Zanubrutinib is indicated for the treatment of people with CLL.  It can be used for newly diagnosed patients and those who have received prior therapy. 

How Does Zanubrutinib Work?

Zanubrutinib works by permanently (covalent) binding to the cysteine residue (Cys481) on the BTK protein, interfering with the survival and growth of CLL cells. 

How is Zanubrutinib Administered?

Zanubrutinib is taken as a tablet by mouth. The standard dosage for zanubrutinib is 160 mg taken twice daily or 320 mg once daily, depending on the patient’s condition and tolerability.

As a continuous therapy, this treatment is taken until the CLL progresses or the side effects become intolerable. 

How Effective is Zanubrutinib for CLL?  

The SEQUOIA study examined the progression-free survival (PFS) rates of zanubrutinib for people with CLL after 4 years of therapy. PFS refers to the percentage of patients in which the cancer has not progressed and/or are alive since the start of treatment. 

• 79% of patients with del(17p) 
• 82% of patients without del(17p) 

Side Effect Profile of Zanubrutinib for CLL

The percentage of people with CLL who experience mild-moderate versions of common side effects from zanubrutinib is shown below. 

For more information on these side effects, you can visit the Side Effects Management section of this guide. 

For more information on zanubrutinib, check out the source below.

• Brukinsa Prescribing Information

Financial Resources for Zanubrutinib

To locate financial resources for zanubrutinib, click here to visit the financial support section of the guide.